Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 55,383 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.09, for a total transaction of $1,943,389.47. Following the sale, the chief financial officer owned 228,938 shares of the company’s stock, valued at approximately $8,033,434.42. The trade was a 19.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $27.43 on Wednesday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $65.30. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The company has a market capitalization of $6.40 billion, a P/E ratio of -43.53 and a beta of 2.40. The company has a fifty day moving average of $32.10 and a 200-day moving average of $26.05.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the firm posted $0.17 earnings per share. The firm’s revenue was up 38.2% on a year-over-year basis. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post -0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in HIMS. Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Hims & Hers Health during the second quarter valued at approximately $11,520,000. Bank of New York Mellon Corp bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $46,220,000. Handelsbanken Fonder AB boosted its position in shares of Hims & Hers Health by 4.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after purchasing an additional 2,300 shares in the last quarter. Valeo Financial Advisors LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $225,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $347,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations, arguing that the agency misunderstands the company’s data-sharing and subscription practices. He also said compounded GLP-1 medications helped lower treatment costs, potentially supporting the company’s broader affordability strategy. Hims & Hers CEO says FTC lawsuit misunderstands how the company works
• Positive Sentiment: An analysis highlighted the Eucalyptus deal as a potential way for Hims & Hers to enter new markets and broaden its international or product reach, offering a possible growth catalyst. Hims & Hers: Eucalyptus Deal Unlocks New Markets
• Neutral Sentiment: Dudum’s CNBC interview also addressed artificial intelligence, the transition from compounded to branded GLP-1 drugs and efforts to reduce healthcare costs. These initiatives could influence the company’s long-term strategy, but they do not resolve the immediate regulatory concerns. Watch CNBC’s full interview with Hims & Hers CEO Andrew Dudum
• Neutral Sentiment: Analysts’ questions following the second-quarter earnings call indicate continued investor scrutiny of growth, profitability and the company’s GLP-1 strategy. The prior quarter featured strong revenue growth but a larger-than-expected loss, increasing the importance of execution. 5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call
• Negative Sentiment: The FTC lawsuit alleges improper business practices involving privacy and billing. The news previously triggered a sharp selloff, and shareholder-law-firm investigations by Hagens Berman, Kessler Topaz and Kaplan Fox are adding legal, compliance and potential securities-liability risks. FTC lawsuit and Hagens Berman investigation
• Negative Sentiment: CFO Oluyemi Okupe sold shares, including 9,388 shares on August 17. However, both disclosed sales were made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making them a limited bearish signal rather than clear evidence of deteriorating confidence. SEC insider transaction filing

Wall Street Analyst Weigh In

Several analysts have issued reports on HIMS shares. Needham & Company LLC upped their target price on Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. UBS Group set a $23.00 price target on shares of Hims & Hers Health in a research note on Friday, May 22nd. Finally, TD Cowen boosted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.